NY-ESO-1：一种免疫原性肿瘤抗原的综述

NY-ESO-1: review of an immunogenic tumor antigen.

作者信息

Gnjatic Sacha, Nishikawa Hiroyoshi, Jungbluth Achim A, Güre Ali O, Ritter Gerd, Jäger Elke, Knuth Alexander, Chen Yao-Tseng, Old Lloyd J

机构信息

Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York 10021, USA.

出版信息

Adv Cancer Res. 2006;95:1-30. doi: 10.1016/S0065-230X(06)95001-5.

DOI:10.1016/S0065-230X(06)95001-5

PMID:16860654

Abstract

In the 9 years since its discovery, cancer-testis antigen NY-ESO-1 has made one of the fastest transitions from molecular, cellular, and immunological description to vaccine and immunotherapy candidate, already tested in various formulations in more than 30 clinical trials worldwide. Its main characteristic resides in its capacity to elicit spontaneous antibody and T-cell responses in a proportion of cancer patients. An overview of immunological findings and immunotherapeutic approaches with NY-ESO-1, as well the role of regulation in NY-ESO-1 immunogenicity, is presented here.

摘要

自发现癌症睾丸抗原NY-ESO-1的9年来，它已成为从分子、细胞和免疫学描述到疫苗及免疫治疗候选物的转变速度最快的物质之一，已经在全球30多项临床试验中以各种配方进行了测试。其主要特点在于它能够在一定比例的癌症患者中引发自发的抗体和T细胞反应。本文概述了NY-ESO-1的免疫学发现和免疫治疗方法，以及调节在NY-ESO-1免疫原性中的作用。